BioWorld

July 7, 2009

Ikaria, BioLineRx Enter Cardiac Licensing Deal Worth $282.5M

Ikaria Holdings Inc. has entered a deal worth a potential $282.5 million with Jerusalem-based BioLineRx Ltd. to license a cardiac remodeling product. (BioWorld Today) Read More

OxiGene Frees up Cash, Product Rights in Low-Priced JV Buyout

Spectrum Spirals on Zevalin Complete Response Letter

FDA Query Gives Confidence to Protalix for Gaucher Drug

Novacta Gets $21M Backing for Antibiotics Development

NIH Finalizes Embryonic Stem Cell Funding Guidelines

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 6, 2025.

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...

EMA warns Ozempic linked to ‘very rare’ side effect

BioWorld

The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...

Aiatella secures €2M for AI-based cardiovascular imaging tech

BioWorld MedTech

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...